News:Treatment
Read the latest news about research on treatments for Alzheimer's disease.
The United States approves the commercialization of a drug that could slow down Alzheimer's disease
The last drug approved by the FDA was in 2003, and until now any treatment has proved to slow down the progression of the disease.
The FDA accepts license application for aducanumab, the first possible disease modifying drug for Alzheimer’s
Dr José Luis Molinuevo comments the possible approval of Biogen’s new treatment, in an interview for the podcast Saving Minds.
Dr. Marc Suárez-Calvet talks about brain rejuvenation for the treatment of Alzheimer’s at the ‘Researcher’s Night’
The aim of the conferences is to bring scientific research closer to people
Dr. José Luis Molinuevo on the closure of Biogen's clinical trials
The scientific director of BBRC's Alzheimer’s Prevention Program suggests trying a new aproach in order to keep working with Aducanumab
BBRC launches new study with umbilical cord blood from the Blood and Tissue Bank
The aim of the project, entitled AlfaAge, is to identify pro-ageing and pro-youthful blood biomarkers in different age groups.
BBRC starts BioAlfa, a novel research on cerebral pro-ageing and pro-youthful blood factors
The project has received funding from the European Union’s Horizon 2020 Research and Innovation Program under the Marie Sklodowska-Curie action grant agreement No 752310.
BBRC researchers participate in the 11th Clinical Trials on Alzheimer’s disease
CTAD conference took place in Barcelona, from the 24th to the 27th of October.
Barcelonaβeta Brain Research Center brings to Spain clinical trials in healthy people to prevent Alzheimer’s disease
The studies will analyze the efficacy of various pharmacological treatments designed to act before the manifestation of the clinical symptoms of the disease.
